It is a disease Alzheimer’s It is the most common form of dementia, but diagnosis remains difficult, especially during the early stages.
Signs of the disease are now being tracked, including abnormal accumulations of amyloid and tau proteins, and neurodegeneration — the slow and gradual loss of nerve cells in specific regions of the brain.
This can be done through a combination of Brain imaging and analysis of cerebrospinal fluid. However, it can be Lumbar puncture It is painful, and people may experience headaches or back pain following the procedure, while brain imaging is expensive and takes a long time to book an appointment.
In this regard, the professor who participated in the study, Thomas Karikare from the University of Pittsburgh in Pennsylvania, USA, said: "Many patients, even in the United States, do not have access to MRI and CT machines, so developing a reliable blood test would be an important step forward.".
He continued: "The blood test is cheaper, safer, and easier to administer, and it might improve clinical confidence in diagnosing Alzheimer’s disease, selecting participants for clinical trials, and monitoring the disease."according to health "Guardian" British.
Although current blood tests can accurately detect abnormalities in the amyloid and tau proteins, detecting signs of damage to the brain’s neurons has been more difficult.
Around the world, Karikari and his colleagues focused on developing blood test document to Antibodieswhich would detect a specific form of tau proteincalled brain-derived tau, which is specific to Alzheimer’s disease, and they applied it to 600 patients.
The next step will be to validate the test in a wider range of patients, including those from diverse racial and ethnic backgrounds, and those with different stages of memory loss or other possible symptoms of dementia.
Karikari also hopes that "Monitoring levels of brain-derived tau in the blood might improve clinical trial design for Alzheimer’s therapies".
“>
And if it is adopted blood test What’s new, the test might enable faster diagnosis of the disease, which means treatment can start earlier.
It is a disease Alzheimer’s It is the most common form of dementia, but diagnosis remains difficult, especially during the early stages.
Signs of the disease are now being tracked, including abnormal accumulations of amyloid and tau proteins, and neurodegeneration — the slow and gradual loss of nerve cells in specific regions of the brain.
This can be done through a combination of Brain imaging and analysis of cerebrospinal fluid. However, it can be Lumbar puncture It is painful, and people may experience headaches or back pain following the procedure, while brain imaging is expensive and takes a long time to book an appointment.
In this regard, Professor Thomas Karikare, who participated in the study, from the University of Pittsburgh in Pennsylvania, said: “Many patients, even in the United States, do not have access to MRI machines and CT machines, so developing a reliable blood test would be a step forward.” mission forward.”
He continued: “The blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s disease, selecting participants for clinical trials, and monitoring the disease,” according to the British “Guardian” health.
Although current blood tests can accurately detect abnormalities in the amyloid and tau proteins, detecting signs of damage to the brain’s neurons has been more difficult.
Around the world, Karikari and his colleagues focused on developing blood test document to Antibodieswhich would detect a specific form of tau proteincalled brain-derived tau, which is specific to Alzheimer’s disease, and they applied it to 600 patients.
The next step will be to validate the test in a wider range of patients, including those from diverse racial and ethnic backgrounds, and those with different stages of memory loss or other possible symptoms of dementia.
Karikari also hopes that “monitoring levels of brain-derived tau in the blood might improve the design of clinical trials for Alzheimer’s therapies.”
